Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥6,913 JPY
Change Today +229.00 / 3.43%
Volume 2.2M
As of 2:00 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - ¥9,756
52 Week Low
10/17/14 - ¥4,074
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; Verastem, Inc.; and Halozyme Therapeutics, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,183 Employees
Last Reported Date: 06/19/15
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥119.0M
Senior Vice President, Chief Executive Office...
Total Annual Compensation: ¥110.0M
Vice President and President of Eisai Global ...
Total Annual Compensation: ¥68.0M
Vice President, President of Eisai Inc and Ch...
Total Annual Compensation: ¥63.0M
Vice President, President of Neuroscience & G...
Total Annual Compensation: ¥97.0M
Compensation as of Fiscal Year 2015.

eisai co ltd (4523) Key Developments

Eisai Co., Ltd. Revises Consolidated Earnings Guidance for the Six Months Ended September 30, 2015

Eisai Co., Ltd. provided consolidated earnings guidance for the six months ended September 30, 2015. For the six months, the company expected revenue of JPY 275,000 million, operating profit of JPY 14,500 million, profit before income taxes of JPY 14,000 million, profit for the year of JPY 9,000 million and basic earnings per share of JPY 30.98 compared to previously expected revenue of JPY 277,500 million, operating profit of JPY 10,000 million, profit before income taxes of JPY 8,400 million, profit for the year of JPY 6,000 million and basic earnings per share of JPY 20.66.

Eisai Co., Ltd. Receives Additional Approval for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations

Eisai Co., Ltd. announced that it has received additional approval for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan. The product will be able to be reimbursed for this newly approved purpose once procedures are completed for insurance reimbursement listing as a specially controlled medical device. DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited as an intravascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. Eisai acquired the exclusive rights to develop and market DC Bead in Japan from Biocompatibles in July 2009 and received manufacturing and marketing approval for the device from Japan's Ministry of Health, Labour and Welfare (MHLW) in April 2013 for use in transcatheter arterial embolization in hepatocellular carcinomas. An AVM is a congenital vascular malformation that leads to various functional, organic and developmental disorders that are caused by an abnormal connection between the arteries and veins disrupting the normal circulation of blood. By selectively embolizing the sections of blood vessels that are supplying nutrients to tumor tissue and malformations, it is possible to necrose or reduce tumors, and improve associated symptoms. It was recommended at the MHLW's Study Council for the Early Introduction of Highly Needed Medical Devices that DC Bead be made available as soon as possible as a device indicated for the treatment of hypervascular tumors as well as AVM. Upon receiving this recommendation, Eisai conducted clinical studies aiming to confirm safety and efficacy of using DC Bead as an embolization material on hypervascular tumors and AVM in Japan in order to secure an indication expansion.

Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma

The Drugs for Neglected Diseases initiative and Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. Most probably transmitted through pricks to the skin by walking barefoot, eumycetoma is a chronic condition that affects people in tropical and subtropical regions, in particular across Africa, with the high burden found in Sudan. The fungus penetrates the skin and causes massive tumour-like lesions that lead to serious disability, grave socioeconomic consequences, and stigma. There is only one current treatment option, which is expensive, toxic, and only cures about 30% of patients even after twelve months of treatment. Those who aren't cured are at risk of repeated amputations as the infection spreads throughout the body. Fosravuconazole, an azole-class antifungal drug discovered by Eisai, has shown in vitro and in vivo to have strong antifungal activities against eumycetoma. Under the terms of the agreement, DNDi and partners will be conducting the clinical development to assess safety and efficacy of fosravuconazole in patients with the disease, while Eisai provides DNDi with its scientific expertise as well as a supply of the drug for the clinical studies. Eisai also has the option to become DNDi's industrial partner to manufacture, register, and make available fosravuconazole at an affordable price to the public sector in endemic areas. Fosravuconazole will be investigated in a randomized controlled trial to study the efficacy of the drug compared to an existing therapy in moderate eumycetoma cases. This study is scheduled to start in 2016, and will be conducted by DNDi in collaboration with the Mycetoma Research Center of the University of Khartoum, Sudan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥6,913.00 JPY +229.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €16.22 EUR -0.03
Nektar Therapeutics $10.78 USD -0.37
Santen Pharmaceutical Co Ltd ¥1,581 JPY +23.00
Shire PLC 4,429 GBp +57.00
Synergy Health PLC 2,337 GBp +37.00
View Industry Companies

Industry Analysis


Industry Average

Valuation 4523 Industry Range
Price/Earnings 47.6x
Price/Sales 3.7x
Price/Book 3.4x
Price/Cash Flow 49.4x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at